Key result
Phosphodiesterase inhibitors significantly decreased plasma brain natriuretic peptide concentrations and prevented the increase in interleukin-6 seen with catecholamines in patients with acutely decompensated heart failure.
Why the study?
Do phosphodiesterase inhibitors compared to catecholamines improve neurohormone and cytokine profiles in patients with acutely decompensated heart failure?
Population
29 patients with acutely decompensated heart failure undergoing monitoring using a Swan-Ganz catheter
Comparison
Phosphodiesterase inhibitors vs Catecholamines
Design
RCT, randomly allocated
Authors
Loading...
May inform inotrope choice favoring phosphodiesterase inhibitors in acute decompensated HF; extends RCT evidence on surrogate profiles.
RCT (n=29)
Initially 1:3, but later 1:1
No
Do phosphodiesterase inhibitors compared to catecholamines improve neurohormone and cytokine profiles in patients with acutely decompensated heart failure?
Absolute Event Rate: 409% vs 753%
p-value: p=<0.01
In patients with acutely decompensated heart failure, phosphodiesterase inhibitors favorably affect neurohormone and cytokine profiles compared to catecholamines.
Kawamura et al. (2001) conducted an RCT in Acutely decompensated heart failure (n=29). Phosphodiesterase inhibitors vs. Catecholamines (dopamine or dobutamine) was evaluated on Plasma brain natriuretic peptide (BNP) concentration at 24 hours (pg/ml) (p=<0.01). Phosphodiesterase inhibitors significantly decreased plasma brain natriuretic peptide concentrations and prevented the increase in interleukin-6 seen with catecholamines in patients with acutely decompensated heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: